Trials / Unknown
UnknownNCT00037128
Study of GL701 in Men With Systemic Lupus Erythematosus
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Genelabs Technologies · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Lupus flares and other symptoms associated with systemic lupus erythematosus (SLE) may be caused by a deficiency of dehydroepiandrosterone (DHEA). GL701 is an investigational new drug meant to enhance DHEA levels. This study is designed to evaluate both the safety and efficacy of GL701 in male lupus patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GL701 |
Timeline
- Start date
- 1998-03-01
- First posted
- 2002-05-17
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00037128. Inclusion in this directory is not an endorsement.